RO7669330

RO7669330 is an **investigational small molecule drug** currently in early clinical development for the treatment of **geographic atrophy (GA)** secondary to **age-related macular degeneration (AMD)**. The compound is being evaluated in a **Phase 1, multi-center, multi-part clinical study** to assess its **safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity** after multiple unilateral intravitreal injections. The primary clinical focus is on ocular and systemic safety in GA, a late-stage, vision-threatening complication of AMD characterized by progressive atrophy of the retinal pigment epithelium and overlying photoreceptors. The precise **mechanism of action** and molecular targets of RO7669330 have not yet been publicly disclosed. The drug is under development and sponsored by **Roche** (Hoffmann-La Roche)[1][2][5][7][9].